High-flux Hemodialysis Versus Hemodiafiltration for End-Stage Renal Disease

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03456232

Enrollment

Registered

2018-03-07

Start date

2017-12-21

Completion date

2018-03-20

Last updated

2018-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Failure

Keywords

hemodialysis, hemodiafiltration, end-stage renal disease

Brief summary

This study evaluates the effect of high-flux hemodialysis compared to hemodiafiltration on small and moderate molecule substances clearance. Meanwhile, this study evaluates the effect of high-flux hemodialysis compared to hemodiafiltration on cardiac function. In this self matching study, participants will receive high-flux hemodialysis compared to hemodiafiltration.

Detailed description

Hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water, is one of the most commonly replacement therapy. Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.

Interventions

OTHERHigh-flux hemodialysis

High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.

OTHERHemodiafiltration

Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 79 Years

Healthy volunteers

Yes

Inclusion criteria

1. Subject has end-stage renal disease. 2. Subject has been on regular dialysis treatment for at least 6 months. 3. Subject has autologous vascular access. 4. Subject is offered thrice weekly hemodialysis. 5. Subject is offered 4 hours duration hemodialysis.

Exclusion criteria

1. Infectious disease 2. Poor echocardiographic window that was unsuitable for interpretation

Design outcomes

Primary

Measure	Time frame	Description
Clearance of moderate molecule substance	4 hours after dialysis	Clearance rate of b2-microglobulin for one dialysis.

Secondary

Measure	Time frame	Description
Left ventricular ejection fraction	4 hours after dialysis	Left ventricular ejection fraction is calculated by dividing the volume of blood pumped from the left ventricle per beat, also known as stroke volume, by the end-diastolic volume.

Countries

China

Contacts

Primary ContactYi Li, Master

13580588265@139.com＋86-20-81346722

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026